These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35992847)
1. Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. Mancini M; De Santis S; Monaldi C; Castagnetti F; Lonetti A; Bruno S; Dan E; Sinigaglia B; Rosti G; Cavo M; Gugliotta G; Soverini S Front Oncol; 2022; 12():901132. PubMed ID: 35992847 [TBL] [Abstract][Full Text] [Related]
2. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263 [TBL] [Abstract][Full Text] [Related]
3. Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells. Mancini M; Monaldi C; De Santis S; Rondoni M; Papayannidis C; Sartor C; Curti A; Bruno S; Cavo M; Soverini S Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35159005 [TBL] [Abstract][Full Text] [Related]
4. Wee1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-γH2AX-MDC1. Zeng F; Peng Y; Qin Y; Wang J; Jiang G; Feng W; Yuan Y Cell Commun Signal; 2022 Dec; 20(1):199. PubMed ID: 36575478 [TBL] [Abstract][Full Text] [Related]
5. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437 [TBL] [Abstract][Full Text] [Related]
6. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia. Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948 [TBL] [Abstract][Full Text] [Related]
7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
8. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells. Flis S; Bratek E; Chojnacki T; Piskorek M; Skorski T Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31614827 [TBL] [Abstract][Full Text] [Related]
10. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150 [TBL] [Abstract][Full Text] [Related]
11. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334 [TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162 [TBL] [Abstract][Full Text] [Related]